Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Corp. (NYSE: NVRO), a medical device company focused on chronic pain treatment solutions, has announced the granting of inducement restricted stock unit awards to 10 new non-executive employees. The awards, approved by the Compensation Committee on January 7, 2025, cover 21,026 shares of Nevro's common stock.
The grants were made under the Nevro Corp. 2023 Inducement Award Plan and will vest over a three-year period, contingent upon continued employment. These awards were granted as material inducements to employment in compliance with NYSE Listed Company Manual Rule 303A.08.
Nevro Corp. (NYSE: NVRO), un'azienda che produce dispositivi medici focalizzati sulle soluzioni per il trattamento del dolore cronico, ha annunciato l'assegnazione di premi in azioni limitate per induzione a 10 nuovi dipendenti non esecutivi. I premi, approvati dal Comitato per i Compensi il 7 gennaio 2025, riguardano 21.026 azioni ordinarie di Nevro.
Le concessioni sono state fatte sotto il Piano di Premi per Induzione 2023 di Nevro Corp. e verranno maturate in un periodo di tre anni, a condizione che continui l'impiego. Questi premi sono stati concessi come indennizzi materiali per l'occupazione in conformità con la Regola 303A.08 del Manuale delle Aziende Quotata NYSE.
Nevro Corp. (NYSE: NVRO), una empresa de dispositivos médicos centrada en soluciones para el tratamiento del dolor crónico, ha anunciado la concesión de premios en forma de unidades restringidas de acciones por inducción a 10 nuevos empleados no ejecutivos. Los premios, aprobados por el Comité de Compensación el 7 de enero de 2025, cubren 21,026 acciones ordinarias de Nevro.
Las concesiones se realizaron bajo el Plan de Premios por Inducción 2023 de Nevro Corp. y se consolidarán durante un período de tres años, condicionado a la continuidad del empleo. Estos premios fueron concedidos como incentivos materiales para el empleo, de conformidad con la Regla 303A.08 del Manual de Empresas Cotizadas de NYSE.
네브로 주식회사(NYSE: NVRO)는 만성 통증 치료 솔루션에 집중하는 의료기기 회사로, 10명의 새로운 비상임 직원에게 유도 제한 주식 단위 상장을 발표했습니다. 이 상장은 2025년 1월 7일 보상위원회에서 승인되었으며, 21,026주의 네브로 보통주를 포함합니다.
이 부여는 네브로 주식회사 2023 유도 상장 계획에 따라 이루어지며, 고용이 유지되는 조건으로 3년 동안 점진적으로 가득 차게 됩니다. 이 상장은 NYSE 상장 회사 매뉴얼 규칙 303A.08에 따라 고용을 위한 물질적 유도로 부여되었습니다.
Nevro Corp. (NYSE: NVRO), une entreprise de dispositifs médicaux axée sur des solutions de traitement de la douleur chronique, a annoncé l'octroi de récompenses en unités d'actions restreintes d'incitation à 10 nouveaux employés non exécutifs. Les récompenses, approuvées par le Comité de rémunération le 7 janvier 2025, portent sur 21,026 actions ordinaires de Nevro.
Les attributions ont été effectuées dans le cadre du Plan d'Attribution d'Incitation 2023 de Nevro Corp. et seront acquises sur une période de trois ans, sous condition de maintien de l'emploi. Ces récompenses ont été accordées comme des incitations matérielles à l'emploi, conformément à la Règle 303A.08 du Manuel des Entreprises Cotées NYSE.
Nevro Corp. (NYSE: NVRO), ein Medizingeräteunternehmen, das sich auf Lösungen zur Behandlung chronischer Schmerzen konzentriert, hat die Gewährung von Induktionsrestricted Stock Units an 10 neue nicht-executive Mitarbeiter bekannt gegeben. Die Auszeichnungen, die am 7. Januar 2025 vom Vergütungsausschuss genehmigt wurden, umfassen 21.026 Aktien des Stammkapitals von Nevro.
Die Zuweisungen wurden unter dem Nevro Corp. 2023 Induktionspreissplan durchgeführt und werden über einen Zeitraum von drei Jahren vesting, abhängig von der Fortsetzung der Beschäftigung. Diese Auszeichnungen wurden als materielle Anreize zur Beschäftigung in Übereinstimmung mit der NYSE Notierte Unternehmensmanual Regel 303A.08 gewährt.
- Stock-based compensation alignment with new employee retention through 3-year vesting period
- Strategic hiring of 10 new non-executive employees indicating company growth
- Potential dilution of existing shareholders through new stock awards
Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in
Nevro also provides minimally invasive treatment options for patients suffering from chronic sacroiliac joint ("SI joint") pain and offers the most comprehensive portfolio of products in the SI joint fusion space, designed to meet the preferences of physicians and varying patient needs in order to improve outcomes and quality of life for patients.
Senza®, Senza II®, Senza Omnia™, and HFX iQ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. Nevro's unique support services provide every patient with an HFX Coach™ throughout their pain relief journey and every physician with Nevrocloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, Nevrocloud, RELIEF MULTIPLIED, HFX AdaptivAI, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents. Bluetooth® and the Bluetooth symbol are registered trademarks of their respective owners.
To learn more about Nevro, connect with us on LinkedIn, X, Facebook, and Instagram.
Investor and Media Contact:
Angie McCabe
Vice President, Investor Relations & Corporate Communications
angeline.mccabe@nevro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-announces-new-employee-inducement-grants-under-nyse-rule-303a08-302356628.html
SOURCE Nevro Corp.
FAQ
How many shares of NVRO stock were granted in the January 2025 inducement awards?
What is the vesting period for NVRO's January 2025 inducement stock awards?
How many new employees received NVRO stock inducement awards in January 2025?
Under which plan were NVRO's January 2025 inducement awards granted?
What NYSE rule authorized NVRO's January 2025 inducement stock grants?
